Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 299

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial

Stone, Gregg W., Bertrand, Michel E., Moses, Jeffrey W., Ohman, E. Magnus, Lincoff, A. Michael, Ware, James H., Pocock, Stuart J., McLaurin, Brent T., Cox, David A., Jafar, M. Zubair, Chandna, Harish, Hartmann, Franz, Leisch, Franz, Strasser, Ruth H., Desaga, Martin, Stuckey, Thomas D., Zelman, Richard B., Lieber, Ira H., Cohen, David J., Mehran, Roxana, White, Harvey D., ACUITY Investigators, for the · 2007 · JAMA

Abstract

CONTEXT: In patients with moderate- and high-risk acute coronary syndromes (ACS) who undergo an early, invasive treatment strategy, current guidelines recommend administration of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors, either upstream to all patients prior to angiography or deferred for selective use in the catheterization laboratory just prior to angioplasty. The preferred approach is undetermined. OBJECTIVE: To determine the optimal strategy for the use of Gp IIb/IIIa inhibitors in patients with moderate- and high-risk ACS undergoing an early, invasive treatment strategy. DESIGN: Prospective, randomized, open-label trial with 30-day clinical follow-up. SETTING: Four hundred fifty academic and community-based institutions in 17 countries. PATIENTS: A total of 9207 patients with moderate- and high-risk ACS undergoing an invasive treatment strategy. INTERVENTIONS: Patients were randomly assigned to receive either routine upstream (n=4605) or deferred selective (n=4602) Gp IIb/IIIa inhibitor administration, respectively. MAIN OUTCOME MEASURES: The primary outcome was assessment of noninferiority of deferred Gp IIb/IIIa inhibitor use compared with upstream administration for the prevention of composite ischemic events (death, myocardial infarction, or unplanned revascularization for ischemia) at 30 days, using a 1-sided alpha level of .025. Major secondary end points included noninferiority or superiority of major bleeding and net clinical outcomes (composite ischemia or major bleeding). RESULTS: Glycoprotein IIb/IIIa inhibitors were used more frequently (98.3% vs 55.7%, respectively) and for a significantly longer duration (median, 18.3 vs 13.1 hours; P<.001) in patients in the upstream group compared with the deferred group. Composite ischemia at 30 days occurred in 7.9% of patients assigned to deferred use compared with 7.1% of patients assigned to upstream administration (relative risk, 1.12; 95% confidence interval, 0.97-1.29; P = .044 for noninferiority; P = .13 for superiority); as such, the criterion for noninferiority was not met. Deferred use compared with upstream use resulted in reduced 30-day rates of major bleeding (4.9% vs 6.1%, respectively; P<.001 for noninferiority; P = .009 for superiority) and similar rates of net clinical outcomes (11.7% vs 11.7%; P<.001 for noninferiority; P = .93 for superiority). CONCLUSIONS: Among patients with moderate- and high-risk ACS undergoing an invasive treatment strategy, deferring the routine upstream use of Gp IIb/IIIa inhibitors for selective administration in the cardiac catheterization laboratory only to patients undergoing percutaneous coronary intervention resulted in a numerical increase in composite ischemia that, while not statistically significant, did not meet the criterion for noninferiority. This finding was offset by a significant reduction in major bleeding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00093158.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.297.6.591

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 299

Metadata

Authors
Stone, G. W., Bertrand, M. E., Moses, J. W., Ohman, E. M., Lincoff, A. M., Ware, J. H., Pocock, S. J., McLaurin, B. T., Cox, D. A., Jafar, M. Z., Chandna, H., Hartmann, F., Leisch, F., Strasser, R. H., Desaga, M., Stuckey, T. D., Zelman, R. B., Lieber, I. H., Cohen, D. J., Mehran, R., White, H. D., & ACUITY Investigators, F. T.
Venue
JAMA
Published
2007-02-14
Volume
297
Issue
6
Pages
591
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2041182304
Cited by
299
References
29
FWCI
25.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. https://app.cochat.ai/papers/10.1001/jama.297.6.591
The paper
Stone, G. W., Bertrand, M. E., Moses, J. W., Ohman, E. M., Lincoff, A. M., Ware, J. H., Pocock, S. J., McLaurin, B. T., Cox, D. A., Jafar, M. Z., Chandna, H., Hartmann, F., Leisch, F., Strasser, R. H., Desaga, M., Stuckey, T. D., Zelman, R. B., Lieber, I. H., Cohen, D. J., . . . ACUITY Investigators, F. T. (2007). Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. JAMA. https://doi.org/10.1001/jama.297.6.591

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.